AstraZeneca Plc (AZN)

40.20
0.02 0.05
NYSE : Health Technology
Prev Close 40.22
Open 40.36
Day Low/High 40.12 / 40.36
52 Wk Low/High 35.30 / 43.30
Volume 1.57M
Avg Volume 3.48M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 104.20B
EPS 0.80
P/E Ratio 18.03
Div & Yield 1.37 (3.39%)

Tax Clampdown Prompts Pfizer to Scrap Allergan Purchase

CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.

Revisiting 3 Promising Small Biotechs

Revisiting 3 Promising Small Biotechs

They are oversold and lately been on the move.

Don't Throw This Biotech 'Baby' Out With the Bathwater

Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.

Don't Throw This Biotech 'Baby' Out With the Bathwater

Don't Throw This Biotech 'Baby' Out With the Bathwater

Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.

Biotech Stocks Are Beginning to Stir

Biotech Stocks Are Beginning to Stir

I am starting to get more confident that the small caps are ready to bounce.

AstraZeneca downgraded at Jefferies

AstraZeneca's Ailment Doesn't Look Treatable

AZN looks vulnerable to further declines. The next downside support area and price target are the $26-$24 area. 

2 Speculative Biotech Stocks for 2016

2 Speculative Biotech Stocks for 2016

Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.

Asian, European Stocks Surge in the Morning of Fed Interest Rate Day

And four other things you need to know now.

Why Relypsa Is a New 'Best Idea'

Why Relypsa Is a New 'Best Idea'

It is hard to see the biotech firm not becoming a takeover target.

Greek Parliament Approves Reforms Required by Creditors

And four other things you need to know now.

Chinese Stocks Close Into Bull Market Territory

And four other things you need to know now.

4 Reasons to Buy High Dividend Yield Equities in Europe

As bond yields go negative, dividend yields shine. 

Searching for a Bottom in AstraZeneca; $34.50 Is the Critical Level

Our strategy for the stock is to look to buy available weakness in the next few weeks.

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge

Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.

Overpriced and Vulnerable: 9 Stocks to Avoid

A look at the high-priced and weak among the most expensive sectors.

Dynavax: Revisiting A 'Best Idea'

Dynavax: Revisiting A 'Best Idea'

This small-cap biotech firm could be in the early stages of a big move.

China Forbids Big Shareholders to Sell Stocks for 6 Months

And four other things you need to know now.

Here Are 3 Charts Showing You Why Illumina Is a Marvel

It's almost impossible to get too excited about its success.

The Amazing Thing About the Receptos Takeover Chatter

That this could be such an open secret is beyond me.

Biotech Moves Are Anything But Crazy

New companies are coming up with major drugs.

Here Are 3 Stocks With Huge Potential

Two are biotechs and one is in cyber security.

Delta Lags Markets on Forex; Boeing Soars on 737 Production

Delta Lags Markets on Forex; Boeing Soars on 737 Production

Delta Air Lines (DAL) lagged the S&P 500 Tuesday after reporting a steep decline in passenger unit revenue in May.

Europe Officials 'Annoyed' With Greece

And four other things you need to know now.

Portfolio Managers Shop for Growth

Combined Heinz-Kraft heads a long second-quarter list.

Dynavax Technologies: A New 'Best Idea'

Dynavax Technologies: A New 'Best Idea'

This vaccine maker is now closer to several important milestones.

Those Sensitive Biotechs

They are prone to being whipsawed by news.

Go With What's Worked, Part 2

Let's look at the other groups that caught fire.

Five Things to Know Now: Another Banking Probe

U.K. authorities launch another probe into banks' conduct.